Related Experiment Video
Updated: Aug 25, 2026
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate
Louis Potters1, David Huang, Paul Fearn
1Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY 11570, USA. pottersl@mskcc.org
Purpose:
To assess the difference in prostate-specific antigen (PSA) response kinetics in patients undergoing either (125)I or (103)Pd permanent prostate brachytherapy (PPB).
Methods And Materials:
Between 1997 and 1999, 333 patients underwent PPB as monotherapy. Forty-eight patients received a (125)I implant, and 285 received a (103)Pd implant. Biochemical relapse-free survival was defined by the Kattan modification of the American Society for Therapeutic Radiology and Oncology consensus, based on three PSA increases. In addition, the time to reach a PSA threshold of
Results:
With a mean 36-month follow-up, the actuarial biochemical relapse-free survival at 4 years was 86.8%. No significant difference in biochemical relapse-free survival was noted between patients treated with (125)I and (103)Pd (p=0.417). Multivariate analysis failed to identify isotope as an independent variable to predict for biochemical relapse-free survival. The mean time for patients treated with (103)Pd to reach the threshold PSA value was 10.2 weeks, whereas it was 22 weeks for (125)I (p=0.014). When the median time to reach the PSA threshold of
Conclusions:
Isotope selection does not appear to influence biochemical relapse-free survival in patients treated with monotherapy PPB. There was a significant difference (p=0.014) in time to reach a PSA threshold of
